- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
MassBio releases Industry Snapshot, Reveals Strong Performance in Massachusetts-Headquartered BioPharma Companies
Companies headquartered in the state raised the fourth highest annual total in the first half of this year.
The Massachusetts Biotechnology Council (MassBio®) today released its 2022 Industry Snapshot, which shows growth across the life sciences industry in 2021 in both workforce and real estate. Venture capital (VC) funding of the biopharma industry remains strong in 2022 despite a downturn in biopharma stock valuations, with the first six months of the year boasting $5 billion invested in Massachusetts-headquartered biopharma companies. Companies located outside of Cambridge, in communities such as Waltham, Bedford, and Watertown, received 57 percent of these investments (up from 42 percent in 2021).
The biopharma research & development (R&D) workforce exhibited 17.2% year-over-year employment growth, second only to California. Meanwhile, the regional expansion of the biomanufacturing industry has led to significant year-over-year employment growth compared with competitor states, growing 15.2 percent between 2020 and 2021. With 1.7 million square feet of Good Manufacturing Practice (GMP) under construction in Massachusetts, this trend is expected to continue.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
